Scottish Funding No For Two Orphans As SMC Tries To Catch Up After COVID-19 Backlog
Two orphan drugs, Chiesi’s Proscybi and Insmed’s Arikayce, were rejected for funding on the Scottish National Health Service.
You may also be interested in...
The norms on securing market access are being rewritten for cell and gene therapies.
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.